Our June, 2021 Quick Question asks, “What is the trademark name of the dabigatran reversal agent?” Here are the answers from our 25 respondents.
- Andexxa: 0%
- Bevyxxa: 8% [2]
- Praxbind: 88% [22]
- KCentra: 0%
- Aripazine: 4% [1]
No one was stumped by this one, perhaps as we had recently posted a question about Andexxa, which reverses the laboratory effects of apixaban and rivaroxaban. Bevyxxa is the trademark for betrixaban, the Portola antithrombotic that was discontinued in April, 2020. KCentra is the four-factor prothrombin complex concentrate whose indication is to reverse the effects of warfarin, and Aripazine [ciraparantag] is a synthetic small molecule that has broad activity against heparin, low molecular weight heparin and dabigatran, rivaroxaban, apixaban, and edoxaban. Aripazine awaits FDA clearance. Thank you to our participants.
No comments here.